How ctDNA is Shaping the Future of Melanoma Care

In this informative webinar, Melissa Wilson, PA-C, MPAS, Melanoma Lead at UPMC Hillman Cancer Center, and medical expert with AIM at Melanoma Foundation, provide an in-depth look at circulating tumor DNA (ctDNA)—a promising new biomarker that is transforming the landscape of melanoma detection, treatment, and monitoring.

What You’ll Learn:

• What is ctDNA? Understand what ctDNA is and how it’s derived from tumor cells into the bloodstream.
• How is ctDNA collected and measured? Discover the non-invasive methods used to collect and analyze ctDNA, including blood tests that are helping to revolutionize cancer diagnostics.
• How can ctDNA be used in melanoma? Explore the current and potential uses of ctDNA in melanoma, including its role in identifying genetic mutations and predicting recurrence, particularly for BRAF-negative melanoma.
• Is ctDNA part of current treatment guidelines? Learn if and how ctDNA is currently incorporated into melanoma treatment plans and clinical guidelines.
• How can ctDNA help me? Find out how ctDNA testing can provide critical insights into your treatment options, monitor disease progression, and potentially guide personalized therapy.
• What future uses can ctDNA have in melanoma? Delve into ongoing research and clinical trials that are exploring the potential of ctDNA in detecting minimal residual disease, predicting treatment response, and monitoring treatment resistance in melanoma.

This webinar is an essential resource for melanoma patients, caregivers, and anyone interested in the latest advancements in melanoma treatment and monitoring.

For more context on understanding whether your immunotherapy is working, see our related resource: Worried Your Immunotherapy Isn’t Working? The Role of ctDNA.

Guest: Zeynep Eroglu, MD, Medical Oncologist at Moffitt Cancer Center and Assistant Professor at the University of South Florida Morsani College of Medicine. Dr. Eroglu is an expert in treating advanced melanoma, involved in clinical trials, and a leader in research on targeted therapies and combination immunotherapy for melanoma.